Impact of a publicly-funded pharmacare program on prescription stimulant use among children and youth

A population-based observational natural experiment

Stimulants are first-line medication treatment for individuals with attention-deficit hyperactivity disorder (ADHD). However, differences in drug coverage may contribute to inequitable access to this treatment. In January 2018, Ontario implemented a publicly-funded program (OHIP+) providing universal access to medications at no cost to children and youth between the ages of 0 and 24. In April 2019, the program was modified to cover only children and youth without private insurance.

This study assesses whether these policy changes were associated with changes in prescription stimulant dispensing to Ontario children and youth.

Access the full article and associated resources:

Please note that this report is NOT COMPLETE and is still in progress. Click below if you would like to continue.